Home / Articles / Tackling Therapeutic Inertia: Why Providers Delay in Diabetes Care

Tackling Therapeutic Inertia: Why Providers Delay in Diabetes Care

Dec 4, 2025
1,116 views
 

In diabetes care, “therapeutic inertia” refers to the failure to escalate or modify treatment when a patient’s glucose control is suboptimal. Even now — when newer, more effective treatments and monitoring tools are widely available — therapeutic inertia in diabetes remains a stubborn barrier. Providers often wait too long before intensifying therapy, leaving many patients under-treated. In this article, we examine why therapeutic inertia in diabetes persists from the clinician’s perspective, and we propose system-level changes that may help ensure timely care.

Table of Contents

  • What is therapeutic inertia in diabetes?
  • Why does therapeutic inertia persist? Causes from the clinician’s perspective
  • Consequences of delayed treatment intensification
  • How system-level changes can address therapeutic inertia
  • FAQs

What is therapeutic inertia in diabetes?

Therapeutic inertia in diabetes describes the situation when a healthcare provider does not adjust a patient’s treatment plan — such as adding medications, intensifying insulin, or increasing monitoring — despite evidence (like elevated HbA1c) that current therapy is insufficient. Source

 

The term covers all stages of care, from first-line oral medications to insulin initiation or intensification. Although treatment options have expanded — including new classes of medications and technology like continuous glucose monitoring — many patients still fail to reach or maintain glycaemic targets. Source

Why does therapeutic inertia persist? Causes from the clinician’s perspective

Clinician concerns and habits

Many clinicians hesitate to intensify therapy due to concerns about risks. Fear of hypoglycemia or weight gain often discourages timely insulin initiation or dose escalation. In one review, over 75% of providers cited hypoglycemia as a barrier to insulin intensification. Source

Providers may also worry about a patient’s ability to manage more complex regimens, especially if social or cognitive limitations are present. Additionally, some clinicians fall into a “wait-and-see” pattern, hoping for improvement without making changes — despite guideline recommendations.

System and workflow barriers

Clinical time constraints and lack of structured workflows can cause missed opportunities for therapy review. Without alerts or care team coordination, treatment intensification may be delayed. Furthermore, there’s no standardized way to measure therapeutic inertia in clinical practice, limiting accountability. Source

Patient-related perceptions

Providers sometimes perceive that patients are not ready or willing for intensified treatment. Concerns about injection fear, side effects, cost, and social support may influence provider decisions. In turn, this perceived reluctance can fuel further delays. Source

Consequences of delayed treatment intensification

When treatment intensification is delayed, patients may remain above their glycemic targets for years. One study found the average delay after crossing HbA1c thresholds ranged from one to seven years. Source

These prolonged periods of uncontrolled diabetes lead to increased risks of complications including retinopathy, nephropathy, neuropathy, and cardiovascular disease. Timely intensification — including early insulin use — can lower A1c and reduce risks without increasing hypoglycemia. Source

How system-level changes can address therapeutic inertia

Team-based care models

Collaborative care involving nurses, pharmacists, and diabetes educators can reduce inertia by distributing responsibilities and improving patient engagement. Studies show team-based care is one of the most effective strategies for overcoming delays. Source

Using EHR-driven prompts

Electronic health records (EHRs) can flag patients who remain uncontrolled for extended periods, prompting providers to reassess care. Programs like the ADA’s Overcoming Therapeutic Inertia initiative recommend this data-driven approach. Source

Creating accountability through metrics

Defining a “therapeutic inertia index” or using quality improvement benchmarks can help clinics monitor progress. Regularly reviewing treatment lag times improves transparency and can motivate earlier intervention. Source

Patient-centered communication frameworks

Using models like ADA’s “Critical Conversations” framework helps clinicians engage patients in proactive decision-making. This can ease fear, foster trust, and support earlier intensification. Source

Continual education and support

Ongoing provider education around medication safety, side effect management, and patient coaching builds confidence to act decisively. Education should extend to patients, too, including access to counseling, nutrition advice, and remote monitoring.

Conclusion

Therapeutic inertia in diabetes is a multifaceted challenge that persists despite modern tools and medications. Clinician hesitancy, workflow limitations, and misperceptions about patient readiness all contribute. Addressing it requires more than individual effort—it calls for system-level transformation. Team-based care, smart use of technology, and structured patient engagement are powerful tools for making timely diabetes care the norm—not the exception.

FAQs

What exactly counts as therapeutic inertia in diabetes?
It’s the failure to adjust a patient’s treatment despite evidence that current care isn’t achieving glycemic goals—such as when HbA1c stays elevated for months without intervention.

How common is it?
Studies suggest that 50–85% of people with type 2 diabetes experience delays in care intensification.

Why do providers hesitate to act?
Concerns include hypoglycemia, patient adherence, cost, time constraints, or the belief that patients aren’t ready for change.

Can tech solutions help?
Yes. EHR alerts, continuous glucose monitors, and better communication tools can all support earlier treatment changes.

What do guidelines say?
Organizations like the ADA recommend reviewing therapy within three months of poor control. Without changes, outcomes worsen over time.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.